罗格列酮对非酒精性脂肪性肝病大鼠肝脏PPARγ、UCP2表达的影响(2)
 |
| 第1页 |
参见附件(3996KB，3页)。
参 考 文 献
[1] Nakamuta M, Kohjima M, Morizono S, et al.Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med,2005,16(4):631-5.
[2] 范建高，丁晓东，王国良，等.高脂饮食性非酒精性脂肪性肝病大鼠肝脏PPARγ表达增强.肝脏,2004,9(4):225-228.
[3] Chavin KD, Yang SQ, Lin HZ, et al. Obesity Induces Expression of Uncoupling Protein-2 in Hepatocytes and Promotes Liver ATP Depletion. J Biol Chem, 1999,274(9):5692-5700.
[4] 范建高，丁晓东，王国良，等.非酒精性脂肪性肝病大鼠肝脏解偶联蛋白2表达及其与能量贮备的关系.中华肝脏病杂志,2005,13(5):374-377.
[5] Kolehmainen M, Uusitupa MIJ, Alhava E, et al. Effect of the Pro12Ala Polymorphism in the Peroxisome Proliferator-Activated Receptor (PPAR) γ2 Gene on the Expression of PPARγ Target Genes in Adipose Tissue of Massively Obese Subjects. The Journal of Clinical Endocrinology & Metabolism,2003,88(4): 1717-1722.
[6] Lee CH, Olson P, Evans RM. Minireview: Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors.Endocrinology,2003,144(6): 2201-2207.
[7] 代东伶，沈薇，张晓红，等.高脂饮食对实验性大鼠非酒精性脂肪肝UCP2表达的影响.国际消化病杂志,2006,26(1):64-66.
[8] 王开成，方朝晖，王佑民，等. 罗格列酮提高胰岛素抵抗大鼠大网膜脂肪细胞PPARγ-mRNA的表达水平.江西医药,2006,41(11):847-850.
[9] 刘章锁, 牛红心, 程根阳,等. 罗格列酮对糖尿病大鼠肾保护机制的研究.中华肾脏病杂志,2004,20(2):109-112.
[10] 熊祖应，黄海长，李惊子，等.过氧化脂质体增殖激活受体-γ对系膜细胞炎症的调控作用.中华医学杂志,2002,82(19):1351-1354.
[11] Strobel A, Siquier K. Effect of thiazolidinediones on expression of UCP2 and adip-ocyte markers in human PAZ6 adipocytes. Diabetologia, 1999,42:527-533.
[12] Tian JY, Li G, Gu YY, et al. Role and mechanism of rosiglitazone on the impairment of insulin secretion induced by free fatty acids on isolated rat islets. Chin Med J (Engl),2006,119(7):574-580.
[13] 吴梧桐.现代生化药学.第1版.北京：中国医药科技出版社，2002：212-215.
[14] 杨桂枝，高小平，晏菊芳，等. 罗格列酮改善胰岛素抵抗细胞摄取葡萄糖的途径研究.四川大学学报(医学版),2007,38(5):816-818.
您现在查看是摘要介绍页，详见PDF附件(3996KB，3页)。